Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Multiple Comparison Tests01:13

Multiple Comparison Tests

Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.

Ophthalmology. Retina·2023
Same author

Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost-Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration.

Ophthalmology and therapy·2023
Same author

Preference-based comparison of quality of life associated with vision loss in Black and White ophthalmic populations in the US.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2022
Same author

Quality of life associated with no light perception vision.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2022
Same author

Re: Le et al.: Associations between age-related eye diseases and Charles Bonnet Syndrome in participants of the Age-Related Eye Disease Study 2: Report Number 26 (Ophthalmology. 2022;129:233-235).

Ophthalmology·2022
Same author

Rural-Urban Comparisons in the Rates of Self-Harm, U.S., 2018.

American journal of preventive medicine·2022
Same journal

Laser vision correction (LASIK, PRK, SMILE) with simultaneous accelerated corneal crosslinking.

Current opinion in ophthalmology·2026
Same journal

Traumatic macular hole: observe, operate, or other options.

Current opinion in ophthalmology·2026
Same journal

The evolving role of artificial intelligence in ophthalmology: basic science, translation, and clinical integration.

Current opinion in ophthalmology·2026
Same journal

Editorial: reducing risk for refractive surgery.

Current opinion in ophthalmology·2026
Same journal

Updates on Refractive Surgery: Benefits, Risks, and Costs of Modern Treatment Options.

Current opinion in ophthalmology·2026
Same journal

Corneal Allogeneic Intrastromal Ring Segments for keratoconus - recent evidence and the move to customized and custom shaped CAIRS.

Current opinion in ophthalmology·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits
08:27

Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits

Published on: September 27, 2019

Comparative effectiveness.

Gary C Brown1, Melissa M Brown

  • 1Center for Value-Based Medicine, Flourtown, PA 19031, USA. gbrown@valuebasedmedicine.com

Current Opinion in Ophthalmology
|April 24, 2009
PubMed
Summary
This summary is machine-generated.

Utility analysis, a quality-of-life instrument, is effective for comparative effectiveness analyses. Physicians should engage in developing comparative effectiveness standards for patient benefit.

More Related Videos

Quantitative Comparison of cis-Regulatory Element (CRE) Activities in Transgenic Drosophila melanogaster
08:19

Quantitative Comparison of cis-Regulatory Element (CRE) Activities in Transgenic Drosophila melanogaster

Published on: December 19, 2011

Related Experiment Videos

Last Updated: Jun 23, 2026

Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits
08:27

Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits

Published on: September 27, 2019

Quantitative Comparison of cis-Regulatory Element (CRE) Activities in Transgenic Drosophila melanogaster
08:19

Quantitative Comparison of cis-Regulatory Element (CRE) Activities in Transgenic Drosophila melanogaster

Published on: December 19, 2011

Area of Science:

  • Health Services Research
  • Medical Decision Making

Background:

  • Comparative effectiveness research (CER) is crucial for evidence-based healthcare decisions.
  • Evaluating healthcare interventions requires robust methodologies to compare outcomes.

Purpose of the Study:

  • To introduce clinicians to the concept and application of comparative effectiveness.
  • To highlight the role of quality-of-life instruments in CER.

Main Methods:

  • Review of recent data on quality-of-life instruments for CER.
  • Focus on utility analysis, specifically time tradeoff utilities.

Main Results:

  • Utility analysis demonstrates high reliability and construct validity for CER.
  • Time tradeoff utilities are suitable for comparative effectiveness analyses across medical specialties.

Conclusions:

  • Physicians must understand and utilize quality-of-life instruments for CER.
  • Active physician involvement in creating CER standards is essential for patient-centered care.